RA Capital Management, L.P.

Institutional investor · Portfolio as of Q2 2026

Q2 2026 biggest moves
  • PBLSPBLS

    Parabilis Medicines

    New listing

    6.9% of portfolio

  • COAGCOAG

    Hemab Therapeutics

    New listing

    2.5% of portfolio

  • DNTHDNTH

    Dianthus Therapeutics

    Sold out

    was 2.3% of portfolio

  • ABVXABVX

    Abivax

    New

    1.3% of portfolio

53 changes in all

Top Holdings84 positions

Checking export access…
Activity:
ASND

Ascendis Pharma A/S

10.3M$2.7B23.8%$137.97+93.32%
7 qtrssince 2024-Q4
Unchanged
0
PBLS

Parabilis Medicines, Inc.

28.9M$791.9M6.9%$27.370.00%
1 qtr
New
98
RYTM

Rhythm Pharmaceuticals, Inc.

6.7M$740.2M6.4%$39.06+184.26%
31 qtrssince 2018-Q4
Unchanged
0
PCVX

Vaxcyte, Inc.

11.5M$667M5.8%$41.48+40.14%
25 qtrssince 2020-Q2
Unchanged
0
SION

Sionna Therapeutics, Inc.

9.9M$435.7M3.8%$10.46+320.55%
6 qtrssince 2025-Q1
Unchanged
0
TYRA

Tyra Biosciences, Inc.

12.2M$389.6M3.4%$16.19+97.32%
20 qtrssince 2021-Q3
Unchanged
0
EWTX

Edgewise Therapeutics, Inc.

8.4M$341M3.0%$17.65+130.21%
10 qtrssince 2024-Q1
Decreased
0
NAMS

NewAmsterdam Pharma Company N.V.

9.6M$323.7M2.8%$13.85+144.66%
15 qtrssince 2022-Q4
Unchanged
0
COAG

Hemab Therapeutics Holdings, Inc.

7.8M$286.8M2.5%$36.730.00%
1 qtr
New
80
SEPN

Septerna, Inc.

7M$234.3M2.0%$22.90+46.24%
7 qtrssince 2024-Q4
Unchanged
0
BCAX

Bicara Therapeutics Inc.

7.3M$215.4M1.9%$25.24+17.63%
8 qtrssince 2024-Q3
Unchanged
0
MLYS

Mineralys Therapeutics, Inc.

7.7M$207.6M1.8%$19.05+41.61%
14 qtrssince 2023-Q1
Unchanged
0
GHRS

GH Research PLC

7.6M$205.3M1.8%$16.65+61.43%
21 qtrssince 2021-Q2
Decreased
0
IRON

Disc Medicine, Inc.

2.5M$179.2M1.6%$57.26+27.74%
6 qtrssince 2025-Q1
Unchanged
0
SGP

SpyGlass Pharma, Inc.

8M$178.6M1.6%$25.91-14.09%
2 qtrssince 2026-Q1
Unchanged
0
ARTV

Artiva Biotherapeutics, Inc.

18M$174.2M1.5%$12.86-24.55%
8 qtrssince 2024-Q3
Increased
74
JANX

Janux Therapeutics, Inc.

11.2M$171.9M1.5%$27.51-44.16%
21 qtrssince 2021-Q2
Unchanged
0
TSHA

Taysha Gene Therapies, Inc.

23.6M$160.4M1.4%$2.70+152.00%
12 qtrssince 2023-Q3
Unchanged
0
BCRX

BioCryst Pharmaceuticals, Inc.

15.8M$158.3M1.4%$7.80+6.79%
3 qtrssince 2025-Q4
Unchanged
0
WVE

Wave Life Sciences, Inc.

27M$156.7M1.4%——
31 qtrssince 2018-Q4
Unchanged
0
$11.5B
AUM
84
Positions
Q2 2026
Filing
HI rating · 2.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$5,987,912,728-20.3120862135%
2025-Q2$5,935,681,007-0.872285942909%
2025-Q3$8,115,527,45836.7244541684%
2025-Q4$9,760,868,19320.2739839587%
2026-Q1$9,437,744,027-3.31040394779%
2026-Q2$11,507,522,06821.9308558812%
Activity profile
$ moved · Q2'26
New56%Increased9%Decreased11%Exited25%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.1 years
<1Q18%1-4Q27%1-2Y14%2Y+40%

RA Capital Management, L.P. manages $11.5B across 84 positions as of Q2 2026. Top holdings: ASND (23.8%), PBLS (6.9%), RYTM (6.4%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.

Top holdings by portfolio weight

Total AUM$12B
ASND23.83%
PBLS6.88%
RYTM6.43%
PCVX5.80%
SION3.79%
TYRA3.39%
EWTX2.96%
NAMS2.81%
COAG2.49%
SEPN2.04%
Other1.87%

Portfolio allocation by GICS sector

Sectors2
Healthcare99.89%
Financial Services0.11%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L24
Conviction65
Concentration92
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
2Q
ARTVARTVArtiva Biotherapeutics, Inc.
Q2 2026 → Q3 2026+8.6M shares+$68.2M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used